The NHS had disapproved to provide financial support to a drug named Lucentis, used in treating diabetic macular oedema (DMO). As per a new direction issued by National Institute for Health and Clinical Excellence (NICE), the drug undervalued the cost of the laser treatment.
To this, Novartis, the producer of the drug was very disappointed and opposed to the decision of NICE. Novartis reveals that the reason of its underrating the laser treatment is that, the treatment only guaranteed prevention of further vision loss, but the drug assured improving the vision in every four out of ten cases.
Even the experiment made on the drug confirmed that the drug is capable of improving the eyesight by reducing the chances of loosing vision by 3%. As per Novartis, “Individuals with visual impairment due to DMO could greatly benefit from ranibizumab, a treatment which can potentially restore vision rapidly, often within a week of receiving the first dose, prevent vision loss and sustain visual improvement”.
Whereas, NICE believed that the company manufacturing the drug undervalued the quantity of the drug that the patient will require in the future. However, Lucentis was approved by the European regulators in January for DMO and is already the standard of treatment for wet aged-related macular degeneration (AMD).